AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)

NCT07555730 · Not yet recruiting

Last updated 2026-05-28

This clinical trial compares an AI-assisted lifestyle program to the medication tirzepatide for maintaining weight loss in adults with type 2 diabetes who are also overweight or obese.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 400 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2026-04 · est. completion 2028-09

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07555730 ↗

Description as written by the study sponsor.

This is a randomized controlled trial to compare the effect of AI-assisted multi-domain lifestyle and continued tirzepatide on body weight loss maintenance. The study consists of two phases: a 20-week lead-in phase, during which all participants will receive weekly subcutaneous tirzepatide at the maximum tolerated dose (MTD), followed by a 52-week intervention phase. Participants who meet the randomization criteria after the lead-in phase will be randomly assigned to either AI-assisted multi-domain lifestyle intervention or tirzepatide 5 mg

Treatments tested

AI assisted multi-domain lifestyle intervention Behavioral

AI-assisted multi-domain lifestyle interventions that integrate dietary, physical activity, and psychological components.
Tirzepatide Drug

Administered subcutaneously.

Main thing measured	Body weight change (kg)
Sponsor	Huazhong University of Science and Technology
Conditions studied	Overweight or Obesity; Type 2 Diabetes, Weight Loss Maintenance
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07555730 ↗